QQ客服 官方微博 反馈留言

	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
	Zhang, Jingru; Wang, Yingqiao; Wang, Jianxiang; Hu, Jianda; Chen, Suning; Jin, Jie; Liu, Ting; Zhou, Jianfeng; Hu, Yu; Ma, Daoxin
刊名	BLOOD CANCER JOURNAL
	2018
卷号	8
DOI	10.1038/s41408-018-0093-4
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4582014
专题	山东大学
作者单位	1.Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Shandong, Peoples R China. 2.[Wang
推荐引用方式 GB/T 7714	Zhang, Jingru,Wang, Yingqiao,Wang, Jianxiang,et al. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance[J]. BLOOD CANCER JOURNAL,2018,8.
APA	Zhang, Jingru.,Wang, Yingqiao.,Wang, Jianxiang.,Hu, Jianda.,Chen, Suning.,...&Geng D.(2018).Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.BLOOD CANCER JOURNAL,8.
MLA	Zhang, Jingru,et al."Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance".BLOOD CANCER JOURNAL 8(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。